Related Experiment Video

Updated: Apr 6, 2026

Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography
07:32

Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography

Published on: March 30, 2022

5.3K

Matrix metalloproteases as a pharmacological target in cardiovascular diseases

E Hopps1, G Caimi

  • 1Dipartimento Biomedico di Medicina Interna e Specialistica, School of Medicine, University of Palermo, Palermo, Italy. eugenia.hopps@unipa.it.

European Review for Medical and Pharmacological Sciences
|July 30, 2015
PubMed
Abstract

Insights

Certain cardiovascular drugs can modulate matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), potentially improving cardiovascular outcomes. Therapeutic strategies should consider targeting MMPs for better heart health.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiology

Background:

  • Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) play a role in atherosclerosis and cardiovascular disease progression.
  • Altered MMP/TIMP profiles are observed in conditions like hypertension, diabetes, obesity, and heart failure.

Purpose of the Study:

  • To review existing literature on the effects of common cardiovascular drugs on MMP and TIMP expression and activity.
  • To explore potential therapeutic strategies targeting MMPs in cardiovascular disease management.

Main Methods:

  • Literature search of PubMed and Medline databases.
  • Keywords included "matrix metalloproteinases," "TIMP," "activity regulation," "pharmacological therapy," "cardiovascular disease," "antihypertensives," "antidiabetic drugs," "statins," and "antiplatelet agents."
  • Inclusion of review articles.

Main Results:

  • Various drugs, including diuretics, calcium-channel blockers, angiotensin receptor blockers, ACE inhibitors, statins, antidiabetic agents, and antiplatelet agents, influence the MMP/TIMP pattern.
  • These drug-induced changes in MMPs and TIMPs appear to have beneficial effects on cardiovascular outcomes.

Conclusions:

  • Current therapeutic strategies may need reconsideration to effectively inhibit MMPs.
  • Targeting MMPs could offer a promising approach for improving cardiovascular health and outcomes.

More Related Videos

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition09:05

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition

Published on: August 20, 2016

8.5K
Measuring Global Cellular Matrix Metalloproteinase and Metabolic Activity in 3D Hydrogels07:39

Measuring Global Cellular Matrix Metalloproteinase and Metabolic Activity in 3D Hydrogels

Published on: January 22, 2019

8.0K

Related Concept Videos

Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
3.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
324